Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623362 | 0.97 | SLC2A1 (0.60) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL30601627 | 0.95 | SLC2A1 (0.65) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5623473 | 0.95 | SLC2A1 (0.65) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5627313 | 0.93 | SLC2A1 (0.57) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5623963 | 0.92 | TP53 (0.53) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5624632 | 0.92 | SLC2A1 (0.56) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5623951 | 0.91 | SLC2A1 (0.69) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5623917 | 0.91 | SLC2A1 (0.54) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5627137 | 0.91 | TP53 (0.51) | SLC2A1KCNH2TP53THRBMAPT | |
| SCHEMBL5891060 | 0.91 | SLC2A1 (0.56) | SLC2A1KCNH2TP53THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | claimed |
| EP-1710238-A1 | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LIMITED (GB) | 2006-10-11 | — | — | EP | claimed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | claimed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | claimed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1710238-A1 | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LIMITED (GB) | 2006-10-11 | — | — | EP | disclosed |
| US-6995283-B2 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060009651-A1 | Benzophenones as inhibitors of reverse transcriptase | CHAN JOSEPH H | 2006-01-12 | — | — | US | disclosed |
| US-20040122064-A1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1363877-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070470-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009651-A1 | Benzophenones as inhibitors of reverse transcriptase | POLRMT, ELL, POLR2A | SLC2A1 3333/4885KCNH2 4082/4885TP53 2233/4885 |
| US-20040122064-A1 | Benzophenones as inhibitors of reverse transcriptase | POLRMT, ELL, POLR2A | SLC2A1 3333/4885KCNH2 4082/4885TP53 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.